Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
Half of all cancer patients fail chemotherapy. This resistance increases mortality and represents a major burden for the health care system.
With approximately 18 million new cancer cases being diagnosed each year, a new treatment that can help overcome chemotherapy resistance could have immense business potential.
Scandion Oncology is working to develop treatments that will re-sensitize cancer cells to chemotherapy within metastatic colorectal and pancreatic cancer.
We believe Scandion Oncology’s approach could help improve outcomes for thousands of cancer patients, creating substantial business potential.
– Bo Rode Hansen, CEO
Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance.
Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.
Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.
We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.